TWI922665B - (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式 - Google Patents

(s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式

Info

Publication number
TWI922665B
TWI922665B TW111115523A TW111115523A TWI922665B TW I922665 B TWI922665 B TW I922665B TW 111115523 A TW111115523 A TW 111115523A TW 111115523 A TW111115523 A TW 111115523A TW I922665 B TWI922665 B TW I922665B
Authority
TW
Taiwan
Prior art keywords
solid form
compound
ray powder
powder diffraction
crystalline
Prior art date
Application number
TW111115523A
Other languages
English (en)
Chinese (zh)
Other versions
TW202309018A (zh
Inventor
史蒂芬 W 卡多爾
托菲克 卡諾尼
安德魯 菲米絲特
潔雅錢德拉 P 雷迪
Original Assignee
法商皮爾法伯製藥公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 法商皮爾法伯製藥公司 filed Critical 法商皮爾法伯製藥公司
Publication of TW202309018A publication Critical patent/TW202309018A/zh
Application granted granted Critical
Publication of TWI922665B publication Critical patent/TWI922665B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW111115523A 2021-04-23 2022-04-22 (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式 TWI922665B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163178752P 2021-04-23 2021-04-23
US63/178,752 2021-04-23

Publications (2)

Publication Number Publication Date
TW202309018A TW202309018A (zh) 2023-03-01
TWI922665B true TWI922665B (zh) 2026-04-21

Family

ID=83723159

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111115523A TWI922665B (zh) 2021-04-23 2022-04-22 (s)-n-(3-(2-(((r)-1-羥基丙-2-基)胺基)-6-嗎啉基吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯啶-1-甲醯胺及其鹽之固態形式

Country Status (12)

Country Link
US (1) US12692248B2 (cg-RX-API-DMAC10.html)
EP (1) EP4326255A4 (cg-RX-API-DMAC10.html)
JP (1) JP7825636B2 (cg-RX-API-DMAC10.html)
KR (1) KR20240000540A (cg-RX-API-DMAC10.html)
CN (1) CN117529313A (cg-RX-API-DMAC10.html)
AU (1) AU2022261159A1 (cg-RX-API-DMAC10.html)
BR (1) BR112023021916A2 (cg-RX-API-DMAC10.html)
CA (1) CA3216258A1 (cg-RX-API-DMAC10.html)
IL (1) IL307910A (cg-RX-API-DMAC10.html)
MX (1) MX2023012521A (cg-RX-API-DMAC10.html)
TW (1) TWI922665B (cg-RX-API-DMAC10.html)
WO (1) WO2022226221A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020371727B2 (en) 2019-10-24 2026-01-22 Pierre Fabre Medicament Inhibitors of RAF kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201443021A (zh) * 2013-03-14 2014-11-16 Novartis Ag 用作激酶抑制劑的二芳基醯胺化合物
WO2020198058A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases
TW202128680A (zh) * 2019-10-24 2021-08-01 美商奇奈特生物製藥公司 Raf激酶抑制劑

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100477070B1 (ko) 1994-03-25 2006-04-21 이소테크니카 인코포레이티드 중수소화작용에의한의약품의효능강화법
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
CA2592118C (en) 2004-12-23 2015-11-17 Deciphera Pharmaceuticals, Llc Urea derivatives as enzyme modulators
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
CL2008001933A1 (es) 2007-06-29 2009-09-25 Millennium Pharm Inc Compuestos derivados de pirimidina, inhibidores de la raf quinasa; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y su uso para tratar trastornos proliferativos, cardiacos, neurodegenerativos, inflamatorios, oseos, inmunologicos enfermedad viral, entre otros.
EP2252612B1 (en) 2008-02-22 2012-03-28 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
JP2012514044A (ja) 2008-12-30 2012-06-21 ミレニアム ファーマシューティカルズ, インコーポレイテッド Rafキナーゼ阻害剤として有用なヘテロアリール化合物
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
KR101652229B1 (ko) 2012-06-07 2016-08-30 데시페라 파마슈티칼스, 엘엘씨. 증식성 질환의 치료를 위한 키나제 저해제로서 유용한 다이하이드로나프타이리딘 및 관련 화합물
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
JP6636014B2 (ja) 2014-09-12 2020-01-29 ノバルティス アーゲー Rafキナーゼ阻害剤としての化合物および組成物
CA3107014A1 (en) 2018-07-31 2020-02-06 AusCann Group Holdings Ltd Solid self-emulsifying pharmaceutical compositions
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
CN114072148A (zh) 2019-05-03 2022-02-18 金耐特生物制药公司 Raf激酶的抑制剂
WO2022060996A1 (en) 2020-09-18 2022-03-24 Kinnate Biopharma Inc. Inhibitors of raf kinases
US11377431B2 (en) 2020-10-12 2022-07-05 Kinnate Biopharma Inc. Inhibitors of RAF kinases
JP7825636B2 (ja) 2021-04-23 2026-03-06 ピエール ファーブル メディカモン (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
TW202308645A (zh) 2021-04-23 2023-03-01 美商奇奈特生物製藥公司 使用raf抑制劑之癌症治療

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201443021A (zh) * 2013-03-14 2014-11-16 Novartis Ag 用作激酶抑制劑的二芳基醯胺化合物
WO2020198058A1 (en) * 2019-03-22 2020-10-01 Kinnate Biopharma Inc. Inhibitors of raf kinases
TW202128680A (zh) * 2019-10-24 2021-08-01 美商奇奈特生物製藥公司 Raf激酶抑制劑

Also Published As

Publication number Publication date
JP7825636B2 (ja) 2026-03-06
BR112023021916A2 (pt) 2023-12-19
MX2023012521A (es) 2023-12-15
US20240208931A1 (en) 2024-06-27
TW202309018A (zh) 2023-03-01
JP2024517431A (ja) 2024-04-22
AU2022261159A1 (en) 2023-11-23
EP4326255A1 (en) 2024-02-28
CN117529313A (zh) 2024-02-06
US12692248B2 (en) 2026-07-28
IL307910A (en) 2023-12-01
CA3216258A1 (en) 2022-10-27
WO2022226221A1 (en) 2022-10-27
KR20240000540A (ko) 2024-01-02
EP4326255A4 (en) 2025-03-12

Similar Documents

Publication Publication Date Title
ES3025633T3 (en) New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
JP2020183408A (ja) {[5−(3−クロロフェニル)−3−ヒドロキシピリジン−2−カルボニル]アミノ}酢酸の固体形態、組成物、及びその使用
JP7825636B2 (ja) (s)-n-(3-(2-(((r)-1-ヒドロキシプロパン-2-イル)アミノ)-6-モルホリノピリジン-4-イル)-4-メチルフェニル)-3-(2,2,2-トリフルオロエチル)ピロリジン-1-カルボキサミドおよびその塩の固体状態での形態
KR20210013554A (ko) Tlr7/tlr8 억제제의 결정질 형태
US10206916B2 (en) Cabozantinib salts and their use as anti-cancer agents
RS61773B1 (sr) Kristalni oblici antagonista androgenog receptora, postupak njihove pripreme i upotrebe
US20240228438A1 (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2- hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
US9453011B2 (en) Crystal form of dabrafenib mesylate and preparation method thereof
US20250059170A1 (en) Solid state forms of an fgfr inhibitor
EP3430004A1 (en) Solid state forms of nilotinib salts
WO2015176591A1 (zh) 贝曲西班盐及其制备方法和用途
TWI705065B (zh) 嗎啉衍生物的鹽及其晶型、其製備方法及藥物組成物、用途
CN110650960B (zh) Acalabrutinib的新晶型及其制备方法和用途
TWI834581B (zh) Lta4h抑制劑的晶型
HK40107041A (en) Solid state forms of (s)-n-(3-(2-(((r)-1-hydroxypropan-2-yl)amino)-6-morpholinopyridin-4-yl)-4-methylphenyl)-3-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and salts thereof
TW202140493A (zh) 2-吲哚啉螺環酮類化合物或其鹽、溶劑錯合物之非晶形式或結晶形式
RU2808992C2 (ru) Кристаллические формы ингибитора lta4h
HK40108981A (en) Solid forms of salts of 4-[5-[(3s)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-ethylpropyl)phenyl]phenyl]-2-fluoro-benzonitrile
TW202602874A (zh) Akt1抑制劑及其鹽之固態形式
WO2025085791A1 (en) Crystalline forms of mrtx0902
BR112021022335B1 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin4-il)-4- metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf, seus usos, e composição farmacêutica
WO2025011642A1 (zh) 一种烟酸酯类化合物的无定型物、多晶型物及其制备方法和应用
JP2023524622A (ja) 6-クロロ-7-(4-(4-クロロベンジル)ピペラジン-1-イル)-2-(1,3-ジメチル-1H-ピラゾール-4-イル)-3H-イミダゾ[4,5-b]ピリジンの塩及び多形体